Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $14 to $18.
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $14 to $18.